According to the information from ten data sets, SMYD1 was significantly downregulated in GC patients (D’Errico et al., 2009), SMYD2 was significantly upregulated in LIHC patients (Chen et al., 2002; Wurmbach et al., 2007; Mas et al., 2009; Roessler et al., 2010), and significantly upregulated in GC patients (Chen et al., 2003; D’Errico et al., 2009; Wang et al., 2012). Here, SMYD1 is linked to gastric cancer.